Danilo. Thanks,
quarter sales, delivery of majority drug XX% second ClearPoint in and is The place taken growth $X XXXX. XXXX in was biologics our which investment where has a in and hiring the by business, record for our quarter plus of Neuro, with driven million
delivery. that conversation the with start Let's pillar of and drug biologics first growth,
academic services. ClearPoint We from than and using partners continue products to gain and traction who and earn are more our XX Neuro pharma business
not and We expect number, to scale grow only these partnerships in in but sophistication.
will multi-platform strategic gene program. therapy earn to the is cash for of product tied A agreement clinical and a drug milestones the blueprint a payment a for Neuro perfect of whereby is this signed itself. regulatory success ClearPoint a example This recently partnership,
drug, of throughout role. development specialists begin the Importantly, where commercial these integral drug milestones Neuro but do an ClearPoint play not approval the a process
agreement would how results. navigating clear a a in touch development a process results that terrific concrete be thus contribute our our successfully can early far. point is only very This of drug the meaningfully our candidate to regulatory in and the This yielding investment possible is example and and process drug because focus of preclinical starts
programs our the space. unique premier the offerings or companies believe While of cancellations expanded make neuro for drug delays in yet us expected, even service are some our portfolio and we product partner
than XX one more program in commercially For potential milestones partners could to $XX products, million drug If generate all and in the per to revenue available. were current ever partnership before is ClearPoint perspective, services XX through dollars of drug their next Phase over trials the preclinical the millions work. X just be candidate, and potential then the hundreds progress Neuro clinical of for from for ClearPoint in years could
Neuroscience, from are treat moderate who this reach of incidence trials commercial disease. announced cash the prior of pathway companies, for from Phase one severe The approval our partner here achieve the operational their FDA announcement clinical and example can regulatory morning to Parkinson's breakeven approvals. to any through IDE They not to depending on is earlier to Aspen key large flow Diego. in message are approval San One X/Xa this we based progression that is here the drug drug that key milestone stage clinical
are them working this be clinical with important We thrilled to on study.
today the only Now company that is greater, and disease, symptoms, epilepsy, of goal these not but event debilitating cetera, achieves will the the these we the much the disease of et onetime drug address do a a potential disease, demand treatments to remember safely in that of Huntington's is like the much to Parkinson's advanced cure symptoms. be gene therapies administration device a than and cure underlying that sometimes the If for drug control interventions these sometimes surgical then commercial simply greater then approval, for could many used itself. cell diseases
there with We not X,XXX expand by the are the annually are demanding a to proven brain X% Parkinson's X treatment. yet and symptoms. number As over deep common in treated just with dramatically are and States struggling or with United control million only than an less of is patients disease patients of and about alone example, that this neurologist That believe even that more living disease. the the stimulation will prescribed population neurosurgeon endorsed even alternatives drug total seeking the
Hiring very expensive expertise, well as neurologist The channel regulatory many get commercial have intellectual the that benefit we economics difficult pharmaceutical due driving focused market the to Neuro for to neurologists has time This endeavor can is not education key a build experience the team reasons. is commercial to also need and neurology change a face scale. setting. in but and Neuro that on to and ClearPoint build of and of already itself. to demand. our partners a our and only our presence is ClearPoint The commercial awareness property, a
When cannula for the of SmartFlow in SmartFlow into the drug brain delivery the differently, only Neuro it Union. Cannula of the was that approval the commercialization, into used ClearPoint the European PTC to was the written Upstaza To of be CE authorization. drug the part say our Mark is for is granted label directly Upstaza European as marketing
and and of and and FDA. clinical drug done the the compatibility bench the for is the for small reason device, This the a preclinical all not device and or documenting is interaction. with show to the for safety which is drug is we essential organize gather notified regulatory The delivery this battery of of testing to that body predictability task
a recent Neuro to version with this product and ClearPoint refining even where delivery has experience data, of decade our of as technology. adding our portfolio therapy saw IP announcement you our and Here's over of a our cell gathering
and are system, future, will pharma administration new the multiple you see targets today. alternative these nervous brain routes to will do we targets deep unlock with of Neuro spine prioritizing partners brain, that to central in the as ClearPoint In the diverse which
drug the So ClearPoint so delivery why and heavily is space. into investing biologics
in in significant worthy on that depending technology, to a not and hospitals even of neurosurgery navigation themselves our have purchase diverse expanding is start just our a maintaining position us the unique very our we It and are believe beneficial our is lead. that base head products. We also where expanse customer to puts more
already space. pharma investing working well-capitalized often into of We and are that the are large hundreds companies millions with
Temporary partners, we think or for ones, downtrends access Neuro's in head this ClearPoint even let's by start existing about or the their true commercial new not have who service can achieved but that environment. to strategy, challenging potential imagine hospital our be we If in development revenue the capital from and a approval value pharma and today procedures have offset so capital spending of XX that drug.
than XX neurologists around more be neuro been would treated. gene be would treating indications. about world cell and educated speaking different sales Patients reps who therapy pharma their with That XX different have available, drugs getting the by
each that company with we is of an so imagine multiple of the our chain. cannulas, co-labeled of one different essential Now these pharma have part drugs become supply
navigation be our but to current a which expand of to commercial because very work at and necessary would new The different our and fraction switching devices ASPs barrier the of costs we not And only to is the able the of device this significant protect a even ASPs a overall and pricing cost nature, for testing high essential several entrants. of because delivery move times necessary are even of procedure. clinical systems,
increased out need announced, want a the leading but the If drug itself along with neurosurgery to procedure. every only as package to that and future already for device hospital and device We will pricing our pharma kick procurement a commercial would in the and base companies of this take will is ClearPoint to be royalties, that earn position expand. further the potentially relationship Neuro real, center then even equation delivery installed also not sales milestones
We roots of new an of part be will essential and care. grow standard this
working in XXXX. of you the in to end is why We believe confident our an space, trial is spending surgical for a why to many we XXX rationale participation continue we lower of gross will itself, for which as sites but installed ability hospitals the temporarily base only and in in not work to which start to relative reach invest feel the clinical That by margin. R&D commercialization, QX the saw
and new development and for continued already we head to cannulas catheters, On delivery solutions. have frame, add procedures dedicated Orchestra the these on like routes not side, new and advanced continued designed to of pump simpler discussed, new like infusion drug and conditional other drills to Maestro only our software MRI we make our administration, technologies more needles but also as have frames development R&D platform affectable faster, the
an at margins reputation value partners. presence performed to to build bring the On responsiveness our to projects and the space, and effort our a in we the preclinical in gross we side, margin show lower
that is of we investment directly our giving this been experience exciting to part we As as us right and look partnerships ahead, already we has business this and strategic valuable believe results. mentioned leads before jump yielding that too the is start
detail, ablation pillar particularly part functional lot in laser of our offset procedures navigation of we but was the somewhat navigation a as laser let's flat epilepsy. year-over-year by navigation. on second of growth was to This growth that was the Now stimulation procedures, saw neurosurgery business relatively the deep brain for move of
rate supply cancellation chain of our epilepsy has that for down rate It increased We due This seems high for illness, market. that and stemming from of staff remained many to ablation come seems COVID increased during be have about navigation the shortages has elevated it issues. of these spoken procedures in a the this procedures. but laser denials reimbursement or even procedures, to laser half for procedures cancellation
process appeal is common sometimes The successful. and
of However, before surgery on for time. days is day. been to and is the that we that the of own the suitable procedures patient place to as certainly to look case to This future. laser common often business find the that we're tumor a another out fill missed has it possible paying couple cases continues and laser MRI where seems not for is number not takes attention denial as scheduled to it result The grow. we the our cancellations often nearly build something itself in
The timing their additional and and revenue the quarter which computer the impacted least on negatively at next our neurosurgery our quarters, part likely business depending the one constraints, of interface had brain to availability to other internal programs due the of delay of the is place that on partners co-development couple of in also for pause on funds.
for multiyear capital will I out for as a happen What quarter capital and revenue our a years. sign up date. process mention another note hospital Similarly, which for of placement. we can launched new down, based timing commitment allows to investment quarter-to-quarter on was are that tool similar. spreads five subscription capital The tool have over the very that This from is a economics installation the
more as service recognition one a a would a than year in purchase, or is rental in day delay placement. first there However, revenue which capital agreement the all it as recognized acts of be of the
We as pilot, have the will service hospitals sign believe popular had ahead. we five for a now years our the in of and subscription option part this up be
As line will not have used these maybe is navigation earnings another year. be all. subscriptions increase we in the but new a represent multiple rentals our to at or result, to our These or first business. flat plan capital not of finish that where operating the start decrease service technologies technologies success also line and capital before the on likely will the only the of future navigation we note, that will in the the room positive designed On for MRI end procedures, the submit tool require be MRI improve the of to to FDA workflow had
will tool fewer As today. the because are operating for for today. this a all taking deployed fast procedures the the to place not see moving XX% of compete product completely a into where not MRI suite on and barriers MRI, performed majority to already and allow This often and DBS than familiar more hospital. in the vast of the room with room users that and transition the procedures new operating reminder, rely laser are more a and workflow potential the can as is physician be ClearPoint the environment from which We us
therapy system our software MRI of growth, tumor. worldwide, therapy For we of as multiple access release expect of epilepsy this of on five with market our have well up new where in including year market the and the pillar first have by end of the installed multiple scanners for installs and made and limited test laser third as as currently we the five our more indications, and PRISM release, to systems as types limited products, We part part system. progress
us give XXXX. These in a launch cases broader build help educational and us for experience materials
We by this of identified the have and will the of dedicated began our team, therapy be cases, year. training support navigation and clinical able which to specialist both laser including end complete
very capability early system. limited the we release, the the ease and are are While our use we of pleased of in with
and delivery first in each exciting operating the expect very the Laser the XXXX. million a the as 'XX all XXXX we the for especially an and with been and platform competitive represents is most feedback supported, contribute system two these in three encouraging, substantially to us ablation, the drug installations for ablation brain and a future. higher product of has three biologics of approximately as to interface Biologics of drug in market more Of we have The pillars applications to performed neuro applications delivery. in The date, should and and clinician $XX and navigation, will team brain multiple our and laser today. plan 'XX years. laser drive next the part deep be PRISM and combined therapy utilization we advantage give in growth driver computer that growth capability biopsy, well the will our room of including neuro stimulation, pillar
about and plus represent If and about think market at all frequently really we development represents number again breakeven, pillar we expectations cash and achieve would XXXX biologics of three which is growth, modest expect QX XX drug exit delivery operational of for something scale hospitals to doing This year and contribution our of cases these our milestones of which pillars prioritize. achieving four global services. profitability, XX a the flow
cash to that sure While we million do profitability. we we in hit make move have toward that $XX.X want available, point and inflection
mentioned in purpose and of and Carlsbad, a a California. companies quality us As capabilities we earlier, including This all reliable see was our our in made well, sophisticated operations, supplier. pharma our that for system, regulatory facility have investments as as ensuring partner new manufacturing clear investment substantial a
team basis. are XX not to than more that a we you With must place working a flying with from audits the understand another Having we strong these these us is pharmaceutical pharma colors companies separate weekly advantage facility can monthly, manufacturing by active in on the pass have partnerships, if audited with and industry that competition. when
to to Similarly, schedule, the we've and States the Irvine, inspected is second with sellable expanded is it capability broader in happy of to to by ClearPoint Carlsbad believe actually quarter. We end multiple this expand of also include underserved the in our investment tool room down produce and only end The regulatory operations winds that completed global be XXXX. a I'm and the customers ahead beyond United report new is they more we product countries powerful the facility when reason of European redundant to to the but real, offering. able by choose one it year that we and of market, clean will the construction see Union. and here our footprint is this California sometimes pharma
to events, larger cash than in on operational XXXX, the first in of half we in some be based timing second As cash burn lower XXXX the of half. seen the expect the
our laser in do services and currently are room new not down operating delivery, access a reflection and this QX, expect that and in launching be devices products therapy, we navigation. of issue more While but long-term a to drug margin biologics we dipped
services at scale. gross margin a product when that some these All new that efforts of new portfolio growth aggregate ramp-up the especially of of to have XX% time we introductions launch have We achieve take with believe of all products introductions. can once products product in some level in again years overtakes ahead, the plus
past and of in us We getting place hard worked continue years. couple of the puzzle see an to front the over exciting pieces all opportunity have in incredibly
and and leverage. focus to resources our is gain scale to existing Now work putting strategy our
we the of end this half we transition cash expect in meaningfully new our of the year decrease manufacturing $XX.X already the mentioned, our as is up have vast facility. and to As the at our majority million and burn second in the head in of quarter count will place operating wrap to
on milestones trials, BLA to focused key six value-creating the the biologic of remain our over PRISM We first the lot to clinical expansion commercial and limited new for the XX system. strategic next of release initiation technology to the that's And months, laser partnerships, drug a executing including new into exiting therapy for market ClearPoint operating using FDA our approval, digest. room submission
up any let's the a and open break take questions. So floor to
